Mirabella Financial Services LLP Has $14.39 Million Position in MaxCyte, Inc. $MXCT

Mirabella Financial Services LLP increased its holdings in shares of MaxCyte, Inc. (NASDAQ:MXCT) by 78.4% during the 2nd quarter, HoldingsChannel reports. The firm owned 6,600,000 shares of the company’s stock after purchasing an additional 2,900,000 shares during the period. MaxCyte comprises approximately 1.5% of Mirabella Financial Services LLP’s holdings, making the stock its 14th largest holding. Mirabella Financial Services LLP owned about 0.06% of MaxCyte worth $14,388,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the stock. Farther Finance Advisors LLC raised its holdings in shares of MaxCyte by 7,935.4% during the second quarter. Farther Finance Advisors LLC now owns 11,812 shares of the company’s stock worth $26,000 after acquiring an additional 11,665 shares during the period. CWM LLC grew its holdings in shares of MaxCyte by 92.7% during the second quarter. CWM LLC now owns 12,132 shares of the company’s stock worth $26,000 after buying an additional 5,836 shares in the last quarter. Prudential Financial Inc. bought a new stake in MaxCyte in the 2nd quarter valued at approximately $26,000. May Hill Capital LLC acquired a new position in MaxCyte during the 2nd quarter worth approximately $27,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in MaxCyte in the second quarter valued at $40,000. 68.81% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on MXCT shares. Wall Street Zen upgraded shares of MaxCyte from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. William Blair downgraded MaxCyte from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 7th. BTIG Research reaffirmed a “neutral” rating on shares of MaxCyte in a research report on Monday, August 11th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of MaxCyte in a research note on Monday. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, MaxCyte has an average rating of “Hold” and an average price target of $7.00.

MaxCyte Trading Up 3.9%

NASDAQ MXCT opened at $1.58 on Friday. MaxCyte, Inc. has a 1-year low of $1.26 and a 1-year high of $5.20. The company has a 50 day moving average of $1.62 and a 200-day moving average of $1.81. The company has a market cap of $168.54 million, a price-to-earnings ratio of -3.59 and a beta of 1.22.

MaxCyte (NASDAQ:MXCT) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). The company had revenue of $6.41 million for the quarter, compared to analyst estimates of $8.37 million. MaxCyte had a negative return on equity of 23.50% and a negative net margin of 132.57%. On average, equities research analysts forecast that MaxCyte, Inc. will post -0.42 earnings per share for the current year.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.